June 2015 Br J Cardiol 2015;22:78 doi:10.5837/bjc.2015.021
Rosie Heath
Introduction Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), causes considerable morbidity and mortality.1 VTE is associated with 370,000 deaths per year in the European Union (EU), an estimated 12% of annual deaths.1 The average incidence of VTE in Europe is approximately 160–180 per 100,000 person-years.1 Three large phase III trials with rivaroxaban, a direct factor Xa inhibitor approved for the treatment and prevention of VTE, have provided a strong safety and efficacy evidence base (table 1). The EINSTEIN-DVT study compared rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg on
February 2014 Br J Cardiol 2014;21:10–11 Online First
BJCardio Staff
ENGAGE AF-TIMI 48: success for edoxaban in AF The new factor Xa inhibitor, edoxaban (Daiichi-Sankyo), was as effective in preventing strokes and safer than warfarin in patients with atrial fibrillation (AF) in the ENGAGE AF-TIMI 48 trial. The ENGAGE AF-TIMI 48 (Effective AnticoaGulation with Factor XA Next Generation in Atrial Fibrillation – Thrombolysis In Myocardial Infarction 48) trial included more than 21,000 AF patients from 46 countries who were randomised to edoxaban at one of two doses (60 mg or 30 mg per day) or warfarin. Results (table 1) showed that both edoxaban doses were associated with significantly less major bleeding than
March 2008 Br J Cardiol 2008;15:87-94
Ian B A Menown
Introduction Culprit artery reperfusion with fibrinolytic therapy and/or percutaneous coronary intervention (PCI) is the established treatment for ST-elevation myocardial infarction (STEMI), with rapid access to optimised treatment providing the best outcome.1,2 Although timely primary PCI compared with fibrinolytic therapy for STEMI has demonstrated potential benefits in mortality and morbidity1 and pilot primary PCI services are currently being evaluated around the UK, fibrinolytic therapy remains the most common form of reperfusion treatment. An area of ongoing research is the optimisation of adjuvant treatment, in particular the anticoagu
November 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 85–AIC 88
Daniel J Blackman, Adrian P Banning
No content available
June 2002 Br J Cardiol 2002;9:356-7
Arpandev Bhattacharyya, Manju Bhavnani, David James Tymms
(more…)
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits